We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · April 23, 2021

Levosimendan Improves Hemodynamics and Exercise Tolerance in Patients With Pulmonary Hypertension and HFpEF

JACC: Heart Failure


Additional Info

JACC: Heart Failure
Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial
JACC Heart Fail 2021 Apr 03;[EPub Ahead of Print], D Burkhoff, BA Borlaug, SJ Shah, R Zolty, RJ Tedford, T Thenappan, RT Zamanian, JA Mazurek, JD Rich, MA Simon, ES Chung, F Raza, DT Majure, GD Lewis, IR Preston, S Rich

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading